Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences
Sharing Progress on a Pipeline of First-in-Class SGK1 Inhibitors Targeting High-Risk Cardiovascular Populations MONTREAL, May 12, 2026 /CNW/…
New Novartis ESC data highlights strength of cardiovascular portfolio
Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS…